Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Bioversys, Aptuit partner to find novel antibiotic targets

Published 08 March 2017

Bioversys and Aptuit have commenced their joint collaboration to identify and validate novel targets and molecules for Gram-negative bacteria.

Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious infections.

BioVersys is focused on the development of small molecules interfering with transcriptional regulation of bacteria, thus addressing novel targets to overcome the threat caused by antibiotic resistance. BioVersys provides one of its most innovative targets focused on Gram-negative pathogens into this collaboration.

Aptuit will provide deep expertise in integrated infectious disease drug discovery, including in vitro and in vivo capabilities, complementing the scientific platform and expertise demonstrated by Bioversys in the transcriptional regulator area.

Bioversys CEO Dr Marc Gitzinger said: “We are excited to collaborate with Aptuit on this project as they have a proven track record in antibacterial drug discovery. At BioVersys we focus on the continuous development of our TRIC technology and on new targets to address the global health threat caused by multi-drug-resistant (MDR) bacteria.

“In Aptuit, we found a strong partner to support us in further developing our innovative therapies”.

Aptuit CEO Dr Jonathan Goldman, CEO, Aptuit said: "I am delighted that Aptuit has been selected to support the development of Bioversys’ innovative project pipeline. This is the result of our continued investment and collaborative approach in this research field.

“As a Partner Research Organization we are fully committed to leveraging our expertise in the renewed challenge associated to the discovery of new effective therapeutics against MDR Gram-negative pathogens”.



Source: Company Press Release